<DOC>
	<DOCNO>NCT03028246</DOCNO>
	<brief_summary>The goal prospective , non-randomized , single-arm , feasibility study develop data evaluate safety feasibility ExAblate 4000 treatment benign intracranial tumor require clinical intervention pediatric young adult subject . Indication Use : Ablation benign intracranial tumor child young adult ExAblate accessible .</brief_summary>
	<brief_title>A Feasibility Safety Study Benign Centrally-Located Intracranial Tumors Pediatric Young Adult Subjects</brief_title>
	<detailed_description>The goal prospective , non-randomized , single-arm , feasibility study develop data evaluate safety feasibility ExAblate 4000 treatment benign intracranial tumor require clinical intervention pediatric young adult subject . Indication Use : Ablation benign intracranial tumor child young adult ExAblate accessible . This feasibility study intend collect data use development future study . As , formal statistical hypothesis hypothesis test propose . The purpose study evaluate safety feasibility manage benign brain tumor size use ExAblate 4000 treatment progress benign intracranial tumor require clinical intervention pediatric young adult subject .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>1 . Males females age 8 22 year schedule neurosurgery , stag recruitment age subcategories oldest young age group . 2 . Subjects benign ( WHO grade I ) centrally locate intracranial tumor require clinical intervention ( see Appendix II ) know carry minimal hemorrhage risk . 3 . Minimum head circumference 52cm 4 . Skull Density Ratio ( SDR ) â‰¥0.40 . 5 . Planned treatment volume exceed 8cm3 6 . Subjects stable dose conditionrelated medication 30 day prior study entry determine medical record . 7 . Cleared general anesthesia ( require ) per local standard . 8 . Subjects and/or parent ( ) /legal representative able willing give inform consent able attend study visit 1 . Subjects unstable cardiac status would increase anesthetic risk include congenital heart disease uncompensated unstable Unstable angina pectoris medication Subjects document myocardial infarction within six month protocol entry Congestive heart failure require medication ( diuretic ) Subjects antiarrhythmic drug 2 . Subjects exhibit behavior ( ) consistent ethanol substance abuse define criterion outline DSMIV manifest one ( ) follow occur within 12 month period : Recurrent substance use result failure fulfill major role obligation work , school , home ( repeat absence poor work performance relate substance use ; substancerelated absence , suspension , expulsion school ; neglect child household ) . Recurrent substance use situation physically hazardous ( drive automobile operate machine impair substance use ) Recurrent substancerelated legal problem ( arrest substance relate disorderly conduct ) Continued substance use despite persistent recurrent social interpersonal problem cause exacerbated effect substance ( example , argument spouse consequence intoxication physical fight ) . 3 . Subjects take human growth hormone ( hGH ) , also know somatotropin 4 . Subjects standard contraindication MR image nonMRI compatible implant metallic device include vagus nerve stimulator , responsive neurostimulator , cardiac pacemaker , nonmetallic shunt , size limitation , etc . 5 . Known intolerance allergy MRI contrast agent ( e.g . Gadolinium Magnevist ) sedative medication 6 . Severely impaired renal function ( estimate glomerular filtration rate &lt; 70 % normal GFR age ) receive dialysis 7 . Any history clinically significant abnormal bleeding and/or coagulopathy 8 . Receiving anticoagulant ( e.g . warfarin ) antiplatelet ( e.g . aspirin , NSAIDs ) therapy within one week focus ultrasound procedure drug know increase risk hemorrhage ( e.g . Avastin ) within one month focus ultrasound procedure ; , unable unwilling stop anticoagulant purpose focus ultrasound procedure . 9 . Subjects use valproate derivative seizure control within precede 2 week ( due inhibitory effect platelet function ) 10 . Known suspected acute , active , uncontrolled infection 11 . History postnatal stroke intracranial hemorrhage within 6 month 12 . Clinical suspicion increase intracranial pressure ( evidence symptom obstruction : headache , nausea , vomit , lethargy , papilledema ) 13 . Have participate another interventional trial last 30 day 14 . History immunocompromise , include subject HIV positive incomplete viral suppression 15 . Known lifethreatening systemic disease 16 . Subjects suicidal ideation previous suicide attempt within past year Unstable psychiatric disease , define active uncontrolled depressive symptom , psychosis , delusion , hallucination , suicidal ideation . Subjects stable , chronic anxiety depressive disorder may include provided medication stable least 60 day prior study entry deem appropriately manage site neuropsychologist 17 . Subjects malignant brain tumor , presence ambiguous clinical feature could imply malignant potential tumor , biopsy necessary 18 . Subjects histopathology important ongoing management 19 . Female subject pregnant , breast feeding planning become pregnant study unwilling practice birth control participation study , childbearing age . 20 . Subjects contraindication anesthesia , judgment attend anesthesiologist 21 . Subjects unwilling unable undergo general anesthesia 22 . Presence condition abnormality opinion Investigator would compromise safety subject quality data . 23 . Minimum head circumference &lt; 52cm 24 . Skull Density Ratio ( SDR ) &lt; 0.40 . 25 . Planned treatment volume &gt; 8cm3</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>